Drug profile · INN
efinaconazole
CLENAFIN
efinaconazole (CLENAFIN) is a lanosterol 14-alpha demethylase inhibitor. Associated with Teva Pharma GmbH. Route of administration: topical. Current US regulatory status: approved.
Drug details — efinaconazole
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
efinaconazole (CLENAFIN) is a lanosterol 14-alpha demethylase inhibitor. Associated with Teva Pharma GmbH. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Lanosterol 14-alpha demethylase inhibitor
Primary target: Lanosterol 14-alpha demethylase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is efinaconazole?
efinaconazole (CLENAFIN) is a lanosterol 14-alpha demethylase inhibitor. Associated with Teva Pharma GmbH. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for efinaconazole?
CLENAFIN is a marketed brand name for efinaconazole. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of efinaconazole?
efinaconazole has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.